[go: up one dir, main page]

DK1417307T3 - Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose - Google Patents

Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose

Info

Publication number
DK1417307T3
DK1417307T3 DK02767738T DK02767738T DK1417307T3 DK 1417307 T3 DK1417307 T3 DK 1417307T3 DK 02767738 T DK02767738 T DK 02767738T DK 02767738 T DK02767738 T DK 02767738T DK 1417307 T3 DK1417307 T3 DK 1417307T3
Authority
DK
Denmark
Prior art keywords
bases
nebularine
hypoxanthine
combinations
uracil
Prior art date
Application number
DK02767738T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Zdenek Richard Holan
Reader Stephanie Dr
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DK1417307T3 publication Critical patent/DK1417307T3/da

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00Subject matter not provided for in other groups of this subclass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/335Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
DK02767738T 2001-08-17 2002-08-19 Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose DK1417307T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17
PCT/IB2002/003323 WO2003016528A2 (en) 2001-08-17 2002-08-19 Oligonucleotide compositions and their use to induce apoptosis

Publications (1)

Publication Number Publication Date
DK1417307T3 true DK1417307T3 (da) 2009-07-13

Family

ID=23215136

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02767738T DK1417307T3 (da) 2001-08-17 2002-08-19 Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose

Country Status (13)

Country Link
US (5) US7199228B2 (da)
EP (2) EP1448986B1 (da)
JP (2) JP4469603B2 (da)
KR (2) KR100943567B1 (da)
AT (2) ATE428781T1 (da)
AU (2) AU2002326067B2 (da)
CA (2) CA2457783A1 (da)
DE (2) DE60211206T2 (da)
DK (1) DK1417307T3 (da)
ES (1) ES2325247T3 (da)
IL (4) IL160408A0 (da)
MX (2) MXPA04001315A (da)
WO (2) WO2003016567A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
AU2001251115A1 (en) * 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
CA2457783A1 (en) * 2001-08-17 2003-02-27 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use to induce apoptosis
AU2003259735A1 (en) * 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
EP2498816A4 (en) * 2009-11-10 2013-12-18 Bioniche Life Sciences Inc POLYNUCLEOTIDE COMPOSITIONS CONTAINING NON-DNA BASES AND THEIR USE FOR MODULATING IMMUNE RESPONSES
US8740314B2 (en) * 2011-01-11 2014-06-03 Joy Mm Delaware, Inc. Bit holding system with an opening for removal of broken bits
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DK0805876T3 (da) * 1995-01-19 2000-11-06 Gen Probe Inc Nukleinsyreamplifikationsoligonukleotider og prober til Lyme-sygdom-associeret Borrelia
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
CA2365980A1 (en) * 1999-04-08 2000-10-19 Oasis Biosciences, Inc. Amplification and sequencing primer pairs and use thereof
ATE455851T1 (de) 1999-12-13 2010-02-15 Bioniche Life Sciences Inc Therapeutisch nützliche synthetische oligonukleotide
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
CA2457783A1 (en) 2001-08-17 2003-02-27 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use to induce apoptosis

Also Published As

Publication number Publication date
KR20040032925A (ko) 2004-04-17
US20030113763A1 (en) 2003-06-19
DE60211206T2 (de) 2006-10-26
WO2003016528A2 (en) 2003-02-27
US8350016B2 (en) 2013-01-08
WO2003016528A3 (en) 2003-10-09
KR100943567B1 (ko) 2010-02-22
US7199228B2 (en) 2007-04-03
DE60211206D1 (de) 2006-06-08
IL160407A0 (en) 2004-07-25
HK1069205A1 (en) 2005-05-13
JP2005509411A (ja) 2005-04-14
JP2005521119A (ja) 2005-07-14
DE60231986D1 (de) 2009-05-28
AU2002330663B2 (en) 2007-09-20
MXPA04001480A (es) 2004-05-20
ATE428781T1 (de) 2009-05-15
WO2003016567A3 (en) 2004-06-03
ATE325341T1 (de) 2006-06-15
US20110160291A1 (en) 2011-06-30
EP1448986B1 (en) 2006-05-03
EP1417307A2 (en) 2004-05-12
AU2002326067B2 (en) 2007-05-31
IL160407A (en) 2010-02-17
JP4504015B2 (ja) 2010-07-14
ES2325247T3 (es) 2009-08-31
US20080081793A1 (en) 2008-04-03
CA2457783A1 (en) 2003-02-27
IL160408A (en) 2010-05-31
CA2457789A1 (en) 2003-02-27
MXPA04001315A (es) 2004-05-20
EP1448986A2 (en) 2004-08-25
US20030144233A1 (en) 2003-07-31
JP4469603B2 (ja) 2010-05-26
KR20040030138A (ko) 2004-04-08
US7200531B2 (en) 2007-04-03
US20080077372A1 (en) 2008-03-27
WO2003016567A2 (en) 2003-02-27
KR101017483B1 (ko) 2011-02-25
EP1417307B1 (en) 2009-04-15
IL160408A0 (en) 2004-07-25
US7893242B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
DK1417307T3 (da) Oligonucleotidsammensætninger og deres anvendelse til at inducere apoptose
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DK1539783T3 (da) Inhibitorer af nucleosidphosphorylaser og nucleosidaser
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
EA200801372A1 (ru) Способы получения замещенных пиримидинов
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
AP2000002016A0 (en) 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives.
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
TR200200278T2 (tr) Kalsilitik bileşimler
DK1339853T3 (da) Isolerede luciferaser og deres anvendelse
BRPI0415355A (pt) triarilimidazóis
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression